Most (if not all) tumors emerge and progress under a strong evolutionary pressure imposed
by trophic, metabolic, immunological, and therapeutic factors. The relative impact of these …

Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, typically
develops on the background of chronic liver disease and is an aggressive disease with …

Lung cancer is a highly heterogeneous disease. Cancer cells and cells within the tumor
microenvironment together determine disease progression, as well as response to or …

Checkpoint inhibitors (CPIs) augment adaptive immunity. Systematic pan-tumor analyses
may reveal the relative importance of tumor-cell-intrinsic and microenvironmental features …

Advances in our understanding of molecular mechanisms of tumorigenesis have translated
into knowledge-based therapies directed against specific oncogenic signaling targets …

Cancer immunotherapies, including adoptive T cell transfer, can be ineffective because
tumors evolve to display antigen-loss-variant clones. Therapies that activate multiple …

The remarkable capacity of immunotherapies to induce durable regression in some patients
with metastatic cancer relies heavily on T cell recognition of tumor-presented antigens. As …

DNA mismatch repair deficiency (MMRd) is associated with a high tumor mutational burden
(TMB) and sensitivity to immune checkpoint blockade (ICB) therapy. Nevertheless, most …

Cancer cells enter a reversible drug-tolerant persister (DTP) state to evade death from
chemotherapy and targeted agents. It is increasingly appreciated that DTPs are important …

Immune checkpoint inhibitors, including antibodies that block programmed cell death protein-
1 (PD-1) and PD-L1, have transformed the management of many cancers. However, the …